Humer Franz B 4

What Happened

• Humer Franz B, a director of Allogene Therapeutics, was awarded 95,400 restricted stock units (RSUs) on 2026-06-18. The grant is reported as a derivative acquisition (code A) with $0.00 per share shown on the Form 4 because these are RSUs (contingent rights to receive shares upon vesting), not an open‑market purchase or cash transaction.

Key Details

• Transaction date: 2026-06-18; Form 4 filed 2026-06-23 (filed five days after the transaction; Form 4s are typically due within two business days).
• Award size: 95,400 RSUs; reported price $0.00 and total reported value $0 (derivative award).
• Shares owned after transaction: not specified in the provided filing.
• Footnote: RSUs vest in two equal semi‑annual installments over one year from the grant date, subject to continued service. The director elected to defer receipt of shares upon vesting under the company's Non‑Employee Director Compensation Policy until the earlier of 30 days after separation or a change in control.

Context

• RSU awards are a form of compensation, not an immediate purchase or sale; no shares are delivered until vesting conditions are met. Such grants are common for directors and typically reflect compensation rather than a direct market sentiment signal. The late filing is a reporting/compliance matter to note but does not by itself indicate trading misconduct.